Biopharmaceutical News and Research

RSS

Topadur’s Phase 2a trial of TOP-N53 for systemic sclerosis-associated digital ulcers advances to next dose levels

Topadur Pharma AG, a Swiss clinical-stage biopharmaceutical company, today announced that the Safety Review Committee of its Phase 2a trial has recommended progression to the next planned dose levels.

5 Nov 2026

Insilico Medicine leader shares AI-driven drug discovery insights in Shanghai and Dubai

Dr. Jue Wang, Head of Global Business Development at Insilico Medicine, has been invited to attend the China Healthcare Summit in Shanghai. On the afternoon of November 3 at 16:45, she will deliver a keynote speech in the panel titled: "THE COMMODITIZATION TRAP: WHO WINS WHEN EVERYONE HAS THE SAME AI?"

30 Oct 2026

DEBRA research invests in Topadur to advance small-molecule therapies for dystrophic Epidermolysis bullosa

DEBRA Research gGmbH, a global non-profit organization dedicated to advancing research and drug development for Epidermolysis bullosa (EB), and Topadur Pharma AG, a Swiss clinical-stage biopharmaceutical company, today announced an investment by DEBRA Research in Topadur to support a preclinical program exploring a new treatment approach for dystrophic Epidermolysis bullosa (DEB). DEB is one of the more severe forms of EB, characterized by extremely fragile skin and progressive, debilitating complications.

28 Oct 2026

Adalvo expands biosimilars portfolio through acquisition of romiplostim biosimilar program from Enzene

Adalvo today announced the acquisition of a romiplostim biosimilar program referencing Nplate® from Enzene, strengthening its biosimilars portfolio and accelerating the company’s expansion into complex biological medicines.

From Adalvo 28 Oct 2026

Maximizing bioprocess efficiency through real-time cell density monitoring

Discover how real-time cell density monitoring boosts yield, lowers media costs, and improves viability in bioprocessing.

From Hamilton AG 21 Oct 2026

Carterra advances lab-in-the-loop drug discovery through new scientific collaboration

Carterra®, a leading provider of high-throughput surface plasmon resonance (HT-SPR™) platforms for antibody and small molecule drug discovery, today announced a research collaboration with AstraZeneca to develop hardware and software aimed at advancing lab-in-the loop drug discovery.

From Carterra Inc. 8 Oct 2026

Photothermal Spectroscopy Corp. launches mIRage®-HSi, delivering more than 30x faster submicron IR imaging

Photothermal Spectroscopy Corp., a leader in submicron infrared spectroscopy and chemical imaging, today announced the launch of the mIRage®-HSi, a high-speed laser-scanning Optical Photothermal Infrared (O-PTIR) microscope delivering more than 30 times faster IR imaging while maintaining sub-500 nm spatial resolution.

From Photothermal Spectroscopy Corp 22 Sep 2026

Submicron IR for pharmaceutical research, development, and quality

The pharmaceutical and biopharmaceutical industries increasingly require rapid, accurate, and high-resolution analytical tools to characterize complex materials, ensure product quality, and accelerate innovation.

From Photothermal Spectroscopy Corp 22 Sep 2026

Congo faces unprecedented Ebola outbreak without approved vaccine protection

As the Ebola outbreak spreads unabated in the Democratic Republic of the Congo (DRC), vaccine developers are scrambling to develop and test a vaccine candidate that will target the species at its center.

21 Sep 2026

Diaceutics launches Precision for All Strategic Collaboration at Fierce Pharma Week 2026

Intelligence and engagement company, Diaceutics, is bringing together senior voices from across the biopharmaceutical industry at the Precision for All Strategic Collaboration, launching at Fierce Pharma Week 2026.

From Diaceutics PLC 18 Sep 2026

ACROBiosystems deepens its France presence with a dedicated hub at The HIVE Innovation Center, embedding into the Campus Grand Parc ecosystem

Kadans Science Partner is pleased to welcome ACROBiosystems to The HIVE Innovation Center, its laboratory and office building dedicated to the life sciences, situated on the Campus Grand Parc in Villejuif.

From ACROBiosystems 16 Sep 2026

African Bundibugyo ebolavirus vaccine candidate to be advanced to clinical trials

Leading African biopharmaceutical company Minapharm Group, headquartered in Egypt with subsidiaries in Berlin, will receive up to US$16.5 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a Bundibugyo ebolavirus vaccine candidate, strengthening efforts to develop vaccines to combat the fastest-growing and second-largest Ebola outbreak on record affecting the Democratic Republic of the Congo (DRC).

28 Aug 2026

New vaccination approach turns mosquito bites into immunity boosters

Researchers from WEHI (Melbourne, Australia) have discovered a new way to help prevent malaria that could one day transform mosquito bites from a source of deadly infection into immunity boosters against the disease.

13 Aug 2026

Air pollution may worsen rheumatoid arthritis symptoms and flare risk

A novel study shows that exposure to air pollution, especially fine particulate matter like dust, soot, and smoke (PM2.5), is associated with increased disease activity and flare risk in rheumatoid arthritis (RA).

5 Aug 2026

Digital twin of the gut-brain axis aims to advance neurostimulation therapies

The gut and brain are in constant conversation, exchanging signals that regulate hunger and digestion, as well as the body's response to stress.

3 Aug 2026

Insilico and Bora Pharmaceuticals forge strategic AI-driven drug discovery alliance

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced a multi-target strategic alliance with Bora Pharmaceuticals Co., Ltd., a global leader in pharmaceutical manufacturing.

14 Jul 2026

Insilico Medicine founder to highlight sustainable longevity at BIO Asia-Taiwan

Dr. Alex Zhavoronkov, Founder and CEO of Insilico Medicine, has been invited to attend BIO Asia-Taiwan, which will be held from July 15 to 19 in Taiwan, China.

11 Jul 2026

ReproNovo announces first participant dosed in EU Phase 2 trial of RPN-002 for embryo implantation

ReproNovo, a clinical-stage biopharmaceutical company committed to addressing critical gaps in male and female fertility as well as women’s health, today announced that the first participant has been dosed in the Company’s EU Phase 2 clinical trial of RPN-002, entitled Nolasiban Optimized Regimen Dosing for Inhibition of Uterine Contractility (NORDIC).

6 Jul 2026

Insilico Medicine partners with Takeda for AI-driven drug discovery

Insilico Medicine, a leader in clinical-stage generative AI for drug discovery, today announced a strategic collaboration agreement with Takeda to use its proprietary end-to-end platform, Pharma.AI, to advance drug candidates across the company's therapeutic areas.

2 Jul 2026

How electrical engineering ensures accurate calibration and patient safety

Discover how electrical engineering supports calibration accuracy, device reliability, and patient safety in critical healthcare applications.

From Mesa Labs, Inc. 22 Jun 2026